AAREYDRUGS vs KOPRAN: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Kopran Limited

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Kopran Limited is the larger company by market capitalisation. Aarey Drugs & Pharmaceuticals Limited shows faster revenue growth, while Kopran Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Kopran Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 5 of 13 scored metrics and KOPRAN on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
KOPRAN is the larger company
₹975 Cr vs ₹221 Cr
P/E Ratio
KOPRAN has a lower P/E
38.28x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 1.86x
EPS
KOPRAN has higher earnings per share
₹3.41 vs ₹1.47
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 0%
Revenue Growth (TTM YoY)
AAREYDRUGS has faster revenue growth
19.8% vs -3.66%
EPS Growth (TTM YoY)
AAREYDRUGS has faster EPS growth
-41.05% vs -71.88%
Qtr Sales Growth
AAREYDRUGS has stronger quarterly sales growth
0% vs -3.03%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSKOPRAN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSKOPRAN
Live Price₹90.51₹206.27
Day Change-4.92%6.56%
Volume2.2 L38.55 L
52-Week High₹96₹219
52-Week Low₹50.31₹107
Distance from 52W High-5.72%-5.81%

Valuation

MetricAAREYDRUGSKOPRAN
Market Cap₹221 Cr₹975 Cr
P/E Ratio55.36x38.28x
P/B Ratio1.46x1.86x
EPS₹1.47₹3.41
Book Value₹48.67₹107.35
Dividend Yield0%1.59%

Growth

MetricAAREYDRUGSKOPRAN
Revenue Growth (TTM YoY)19.8%-3.66%
EPS Growth (TTM YoY)-41.05%-71.88%
Qtr Sales Growth0%-3.03%
Qtr Profit Growth0%-32.9%

Profitability & Leverage

MetricAAREYDRUGSKOPRAN
ROE2.64%4.85%
ROCE6%9.75%
Net Margin0.84%3.78%
Operating Margin2.21%6.58%
Debt to Equity0.33x0.29x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSKOPRAN
Promoter Holding37.71% 1.35 pp44.42%
FII Holding4.18% 0.32 pp0.51% 0.06 pp
DII Holding1.62% 1.62 pp0%
Public Holding56.49% 0.6 pp55.06% 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Kopran Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.